A Phase 1/2 Dose Finding Study of Poziotinib in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 09 Jul 2024
At a glance
- Drugs Poziotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
Most Recent Events
- 12 Jul 2023 Status changed from active, no longer recruiting to discontinued.
- 27 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2020 Status changed from not yet recruiting to recruiting.